Influenza vaccine testimony

This white paper by Chiron Corp. describes the influenza vaccine through which millions of potentially fatal infections have been prevented. This white paper also provides an overview of Chiron which is the second-largest producer of influenza vaccines in the world. Also discussed are the egg-based influenza vaccine production and the supply of influenza vaccines in interpandemic years and that the focus has been on preventing the occurrence of shortage of vaccine. In this white paper, U.S. influenza supply in a pandemic is discussed and that the factors like production capacity, inability to stockpile, supply of primary production material, and specialized production facilities limit the ability to rapidly expand supply in the face of a pandemic. Year-round production and monovalent vaccine should be undertaken to increase vaccine production.

Published:	2004
Format:	PDF
Length:	15 pages
Type:	White paper
Language:	English

• Email This Page
• Print This Page